About The Test
Health Care Providers
Patients
Pharma & Biotech
Knowledge Hub
About Biovica
Contact Biovica

Clinical Evidence

news-noimage-divitum

SWOG S0226 Trial

Metastatic Breast Cancer
Monday 15 November 2021

news-noimage-divitum

More breast cancer references

Metastatic Breast Cancer
Wednesday 1 January 2020

Previous«
1
2

DiviTum^® TKa is CE marked in Europe and FDA 510(k) cleared in the United States.

The DiviTum^® TKa method and kit are protected under
US Patent Nos. 8,765,378 and 9,376,707.
Patent protection in 49 countries.
DiviTum^® is a registered trademark of Biovica International AB.

Sitemap

Home
About The Test
Health Care Providers
Patients
Pharma & Biotech
Knowledge Hub
Privacy Policy
Terms And Conditions
About Us
Contact Us

Sweden

info@biovica.com

+46 (0) 18 44 44 830

Dag Hammarskjölds väg 54
Uppsala Science Park 752 37 Uppsala

USA
us@biovica.com

Main: +1 (858) 230-6044
Fax: +1 (858) 230-6174

6195 Cornerstone Court E
Suite 101
San Diego, CA 92121

Follow us

facebook
linkedin
x
youtube

© 2023 Biovica International AB. All Rights Reserved.
About cookies

Search

Search on Divitum.com

Required

PLEASE SELECT ONE

Please specify your home location

USA

Europe/Rest of World